Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash & Equivalents (2016 - 2025)

Adma Biologics' Cash & Equivalents history spans 14 years, with the latest figure at $87.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 15.04% year-over-year to $87.6 million; the TTM value through Dec 2025 reached $87.6 million, down 15.04%, while the annual FY2025 figure was $87.6 million, 15.04% down from the prior year.
  • Cash & Equivalents reached $87.6 million in Q4 2025 per ADMA's latest filing, up from $61.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $103.1 million in Q4 2024 to a low of $34.4 million in Q3 2021.
  • Average Cash & Equivalents over 5 years is $66.2 million, with a median of $65.9 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: tumbled 42.34% in 2021, then surged 112.57% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $51.1 million in 2021, then soared by 69.36% to $86.5 million in 2022, then tumbled by 40.65% to $51.4 million in 2023, then skyrocketed by 100.86% to $103.1 million in 2024, then dropped by 15.04% to $87.6 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Cash & Equivalents are $87.6 million (Q4 2025), $61.4 million (Q3 2025), and $90.3 million (Q2 2025).